This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Brey, R. Articles by Stallworth, C. Search for Related Content PubMed PubMed Citation Articles by Brey, R. Articles by Stallworth, C. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Brain Diseases Lupus Peripheral Nerve Disorders Social Bookmarking                         What's this?

Anti-Intercellular Adhesion Molecule-1 (ICAM-1) antibody treatment prevents central and peripheral nervous system disease in autoimmune-prone mice

Departments of Neurology and Pathology, University of Texas Health Science Center at San Antonio, Texas, USA

AA Amato

Departments of Neurology and Pathology, University of Texas Health Science Center at San Antonio, Texas, USA

K. Kagan-Hallet

Departments of Neurology and Pathology, University of Texas Health Science Center at San Antonio, Texas, USA

CB Rhine

Departments of Neurology and Pathology, University of Texas Health Science Center at San Antonio, Texas, USA

CL Stallworth

Departments of Neurology and Pathology, University of Texas Health Science Center at San Antonio, Texas, USA

Abnormal neurological functioning similar to that seen in systemic lupus erythematosus (SLE) patients is detectable in an SLE-prone murine strain (MRL/1pr) by 8-10 weeks and is severe by 18 weeks of age. The purpose of this study was to evaluate the effectiveness of murine anti- intercellular adhesion molecule-1 (ICAM-1) in suppressing neurological disease in MRL/1pr mice. Beginning at 6 weeks of age, five MRL/1pr mice received 5 weekly intraperitoneal injections of anti-ICAM-1-containing culture supernatant in phosphate-buffered saline (PBS) whereas four animals were treated with non-anti-ICAM-1 containing supernatant in PBS. A decline in neurological functioning began in control mice by 10 weeks, but anti-ICAM-1 treated mice remained normal throughout the study. All control mice had vasculitic skin lesions by 14 weeks of age whereas none of the anti-ICAM-1 treated mice ever developed skin lesions. Nerve conduction studies performed on all mice prior to sacrifice showed sciatic compound motor action potentials of anti-ICAM-1 treated mice that were of higher amplitude and shorter latency than those of controls. Inflammation in the sciatic nerve was more common in control mice. Brain histology revealed a similar degree of choroid plexus inflammation in both groups. Our study demonstrated that anti- ICAM-1 was effective in suppressing neurological abnormalities in MRL/1pr mice and may potentially be useful therapy in human SLE.

Key Words: intercellular adhesion molecule-1 • MRL/1pr mice • systemic lupus erythematosus • nerve conduction studies

Lupus, Vol. 6, No. 8, 645-651 (1997)
DOI: 10.1177/096120339700600805


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?